SCHEMBL7216865

SCHEMBL7216865

Fc1ccc(C([CH]CN2CCCC2)c2ccncc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.43
SLC6A3 Q01959 2/20 0.40
LTA4H P09960 1/20 0.40
MAPK13 O15264 2/20 0.38
MAPK12 P53778 2/20 0.38
MAPK11 Q15759 2/20 0.38
MAPK14 Q16539 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
SIGMAR1 Q99720 2/20 0.37
LMNA P02545 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
SCN5A Q14524 1/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2D6 P10635 2/20 0.36
MEN1 O00255 1/20 0.36
CYP2C9 P11712 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7216927 0.87 KDM4E (0.49) ACHESLC6A3MAPK13MAPK12MAPK11
SCHEMBL7216729 0.86 ACHE (0.48) ACHESLC6A3LTA4HMAPK13MAPK12
SCHEMBL7220444 0.85 PRCP (0.41) SLC6A3NPSR1HTR2AHTR2COPRM1
SCHEMBL7217023 0.85 ACHE (0.49) ACHESLC6A3LTA4HMAPK13MAPK12
SCHEMBL7215357 0.80 PRCP (0.40) SLC6A3NPSR1CYP3A4MEN1THPO
SCHEMBL7214547 0.80 MAOB (0.39) SLC6A3LMNANPSR1CYP3A4MEN1
SCHEMBL7214446 0.79 NPC1 (0.38) SLC6A3SIGMAR1NPSR1MEN1MAPK1
SCHEMBL7215286 0.78 KMT2A (0.46) NPSR1MEN1KMT2AUSP2TSHR
SCHEMBL7216749 0.74 LOXL2 (0.38) SLC6A3LTA4HMAPK14USP2
SCHEMBL7220239 0.74 ACHE (0.52) ACHESLC6A3MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6630485-B2 For therapy of inflammatory disease SYNTEX (U.S.A.) LLC 2003-10-07 US disclosed
US-6479507-B2 MODULATION OF THESE INFLAMMATORY CYTOKINES IS CONSIDERED ONE OF THE MOST EFFECTIVE STRATEGIES TO BLOCK CHRONIC INFLAMMATION AND HAVE POSITIVE THERAPEUTIC OUTCOMES SYNTEX (U.S.A.) LLC 2002-11-12 US disclosed
US-6316464-B1 P38 MAP kinase inhibitors SYNTEX (U.S.A.) LLC 2001-11-13 US disclosed